Syntara the science explained, page-65

Welcome on board@Jakjazz

Couple of near term catalysts on the way here at SNT , should start seeing the heat turn up shortly , October / November Phase II Sweetspot , December for Results and presentation of Phase II data in the States...

You already know the value of the below nugget in bold and underlined... no same same drug.... NZT

My initial focus is the Phase II SNT 6302 ,

This is from the Phase I Trial Announcement
Comments from : Professor Fiona Wood AM and researchers atThe University of Western Australia (UWA),

1st Quote " ...6302, formulated in a cream, is a first in class inhibitor of the lysyl oxidase enzymes (LOX) thatare involved in formation and maintenance of scars and is a potential breakthrough treatment forpatients with problematic scars.

2nd Quote
"We estimate that upto 50% of the excess collagen in these patients’ scars has been removed..."

Dermal / Skin Scaring is incredibly visual and easily interpreted by investors... simple before and after shots will pay dividends for this company ..NZT